Standout Papers

Cardiovascular Outcomes wi... 2004 2026 2011 2018 962
  1. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes (2020)
    Christopher P. Cannon, Richard E. Pratley et al. New England Journal of Medicine
  2. Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol (2004)
    Margaret E. Brousseau, Ernst J. Schaefer et al. New England Journal of Medicine

Immediate Impact

1 by Nobel laureates 8 from Science/Nature 78 standout
Sub-graph 1 of 16

Citing Papers

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
2023 Standout
Type 2 diabetes
2022 Standout
21 intermediate papers

Works of James P. Mancuso being referenced

Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial
2022
Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study
2017
and 6 more

Author Peers

Author Last Decade Papers Cites
James P. Mancuso 2467 1106 1363 42 3.1k
Weichung Shih 1955 1009 792 31 2.7k
M.J. Whiting 1669 938 1564 39 3.6k
Jennifer Sugg 2742 1597 1453 64 4.4k
Michel Komajda 1686 812 1655 24 3.4k
Franklin J. Zieve 3083 1249 1276 43 4.9k
James M. Luther 1133 745 582 69 2.6k
Valentine Charlton-Menys 2132 690 2241 37 4.4k
Klaus A. Dugi 2880 1401 1526 71 4.3k
Leo Seman 1415 659 1245 42 2.1k
Anette Fiebeler 1314 1183 831 60 4.0k

All Works

Loading papers...

Rankless by CCL
2026